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ABSTRACT
Epithelial Ovarian Cancer (EOC) is associated with dismal survival rates due to 
the fact that patients are frequently diagnosed at an advanced stage and eventually 
become resistant to traditional chemotherapeutics. Hence, there is a crucial need 
for new and innovative therapies. Septin-2, a member of the septin family of GTP 
binding proteins, has been characterized in EOC for the first time and represents a 
potential future target. Septin-2 was found to be overexpressed in serous and clear 
cell human patient tissue compared to benign disease. Stable septin-2 knockdown 
clones developed in an ovarian cancer cell line exhibited a significant decrease in 
proliferation rates. Comparative label-free proteomic analysis of septin-2 knockdown 
cells revealed differential protein expression of pathways associated with the 
TCA cycle, acetyl CoA, proteasome and spliceosome. Further validation of target 
proteins indicated that septin-2 plays a predominant role in post-transcriptional and 
translational modifications as well as cellular metabolism, and suggested the potential 
novel role of septin-2 in promoting EOC tumorigenesis through these mechanisms.
INTRODUCTION
Epithelial Ovarian Cancer (EOC) is the most 
lethal gynecologic malignancy [1]. In 2018, there will 
be an estimated 22,240 new cases of EOC diagnosed and 
14,070 deaths in the United States. While EOC accounts 
for only 2.5 % of all female cancers, it is responsible for 
5% of all cancer deaths due to low disease survival rates 
[2]. These dire statistics are attributed to the fact that the 
majority of patients are diagnosed at an advanced stage. In 
addition, while patients generally respond well to frontline 
platinum-based chemotherapy, chemoresistant recurrences 
are common [3]. Therefore, there is a strong need for 
novel early detection methods and targeted therapies for 
EOC patients.
Septin-2 is a member of the septin family, a 
conserved family comprised of 13 GTP binding proteins 
[4]. Septins, which are structurally observed as rods and 
filaments, are vital to a number of cellular processes, 
including cytokinesis, vesicle trafficking, and exocytosis 
[5]. They are considered to be a fourth component of 
the cytoskeleton due to their association with actin, 
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microtubules, and membranes [6]. Septins have been 
identified as having a role in neurodegenerative disease, 
since they were detected in brain tissue from patients 
with Alzheimer disease [7]. In addition, they have been 
reported to be involved in bacterial infections, Parkinson’s 
disease, and male infertility [8].
In more recent years, emphasis has been placed 
on investigating the role of septins in tumorigenesis 
[9]. Due to their natural function in scaffolding and 
membrane compartmentalization, it is plausible that they 
could also play a role in the organization of membrane 
associated proteins involved in diverse tumorigenic 
signaling pathways [6]. Septin-9 is the most well studied 
septin family member in relationship to cancer, and its 
methylation status is utilized as a biomarker in colorectal 
cancer [10]. However, there have also been numerous 
studies linking septin-2 to neoplasia. Thus far, septin-2 has 
been specifically implicated in Hodgkin’s lymphoma and 
biliary tract, gastric, hepatocellular, renal cell carcinoma, 
and breast cancer [11–17]. However, septin-2’s role in 
EOC has not been previously investigated.
In this study, we begin to elucidate septin-2’s 
function in EOC. As septins have been shown to have 
diverse roles in tumorigenesis, this is the first step in 
specifically defining septin-2’s contribution to EOC 
pathogenesis. To establish the clinical relevance of 
septin-2 in EOC, we first sought to compare levels of 
septin-2 in various histological pathologies of EOC versus 
benign disease. Furthermore, we present for the first time 
a global analysis of septin-2 mediated proteomics in EOC 
and describe signaling pathways most affected by septin-2 
depletion. The results from this study lay the framework 
for future mechanistic studies to determine the precise role 
of septin-2 in EOC.
RESULTS
Septin-2 is overexpressed in EOC
To establish the clinical relevance of septin-2 in 
EOC, we evaluated its levels in EOC samples of a variety 
of histologies, and compared these to levels in benign 
controls. Immunohistochemical analysis of septin-2 
levels in a human ovarian tissue microarray comprising 
normal, serous, mucinous, clear cell, and dysgerminoma 
histopathologies revealed that mean intensity of the 
septin-2 staining was statistically significantly greater in 
serous EOC (703.38 pixels) than in adjacent normal tissue 
(539 pixels) (p = 0.0037) (Figure 1A). While all other 
histopatholgies exhibited higher mean intensity levels of 
septin-2—mucinous (603 pixels), clear cell (821 pixels), 
and dysgerminoma (744 pixels)—compared to the normal 
adjacent tissue, none were considered statistically significant, 
possibly due to low numbers of samples available.
To further investigate expression levels of septin-2 
in patient samples, immunohistochemistry of septin-2 was 
performed in EOC and benign tissue from our institution. 
Integrated optical density (IOD) was calculated for each 
sample, which revealed statistically significant higher 
levels in serous (721 area*mean/1E+06, p = 0.04) 
(Figure 1B–1C) and clear cell (31 area*mean/1E+06, 
p = 0.009) histopathologies (Figure 1D–1E) compared to 
respective benign controls (239 area*mean/1E+06) and (6 
area*mean/1E+06). Staining results were further validated 
with an independent antibody in five clear cell EOC, five 
serous EOC and four benign samples (Supplementary 
Figure 1A–1B).
Stable knockdown of septin-2 influences cell 
proliferation
In order to study septin-2’s function in EOC, stable 
septin-2 knockdown shRNA clones were generated in 
human serous ovarian SKOV3 wild type (WT) cells. Two 
clonal populations were employed for these studies—
knockdown 9 (KD9) and knockdown 11 (KD11)—based 
on confirmation of successful septin-2 downregulation. 
A stable line was also generated by clonal expansion of 
cells transfected with scrambled oligo control shRNA, 
designated Plasmid C. To confirm the efficacy of 
knockdowns at the genomic level, qPCR was employed. 
Septin-2 levels in KD9 were 1.93- and 4.16-fold lower 
than WT and Plasmid C cells, respectively. Septin-2 levels 
in KD11 were 1.67- and 3.88-fold lower than WT and 
Plasmid C cells, respectively (Figure 2A).
To further validate successful knockdown of septin-2, 
protein levels were detected by Western blot. We observed 
substantial decreases in septin-2 levels in KD9 and KD11 
compared to the WT and Plasmid C controls (Figure 2B). 
Septin-2 levels in KD9 were 0.28-fold relative to WT and 
0.38-fold reduced relative to Plasmid C. Septin-2 levels in 
KD11 were 0.24-fold and 0.32-fold reduced relative to WT 
and Plasmid C, respectively (Figure 2C).
To begin to determine the consequence of septin-2 
knockdown in SKOV3 cells, proliferation of the shRNA 
clones was evaluated. WT, Plasmid C, KD9, and KD11 
cells were seeded at equal cell densities and allowed to 
expand. The cells were trypsinized at 72 and 96 hours, 
and numbers of live cells in each clonal population were 
quantified (Figure 2D). At 72 hours, KD9 clones exhibited 
a 0.33-fold reduction in cell proliferation compared to WT, 
and a 0.40-fold reduction compared to Plasmid C. KD11 
clones demonstrated a 0.34-fold and 0.41-fold reduction 
in proliferation from respective WT and Plasmid C cell 
numbers. The 96-hour time point revealed a 0.49-fold 
reduction in KD9 cells compared to WT and a 0.61-fold 
reduction compared to Plasmid C. KD11 cells showed 
a 0.37-fold and 0.46 fold- decrease compared to WT 
and Plasmid C cells, respectively. All decreases in cell 
counts displayed by KD9 and KD11 at both time points 
were determined to be statistically significant (p < 0.02). 
Differences in viability between WT, Plasmid C, KD9, 
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and KD11 determined by live/dead counts were found to 
be non-significant (Supplementary Figure 2), confirming 
that our findings were not due to increased cell death. 
This finding strongly suggests that the downregulation 
of septin-2 has a profound impact on cell proliferation in 
EOC cells.
Proteomic analysis of septin-2 knockdown in 
EOC cells
A comparative label-free proteomic analysis was 
performed to examine global protein expression level 
differences resulting from the knockdown of septin-2. 
Figure 1: Septin-2 is overexpressed in EOC. (A) A commercially available human ovarian tissue microarray was stained with 
Septin-2 primary antibody and examined by confocal microscopy. Staining in all histopathogies was then quantified via mean intensity. 
(B) Paraffin-embedded human EOC tissue slides were stained for Septin-2 and expression was analyzed by integrated optical density. (C) 
Representative images of Serous EOC staining (left panel) vs benign (right panel). (D) Staining of paraffin-embedded human clear cell 
EOC tissue and benign controls with septin-2 was performed and expression was assessed by IOD. (E) Representative images of clear cell 
EOC staining (left panel) vs benign (right panel).
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Interestingly, significant differences in protein-peptide 
levels between control cells and septin-2 knockdowns 
was observed only in KD11 populations, even though our 
proliferation results demonstrated that KD9’s phenotype 
was similar to that of KD (Supplementary Dataset). In 
order to test the hypothesis that spontaneous loss of the 
knockdown had occurred in KD9 cells during cell culture, 
we reexamined septin-2 levels in each of the clonal cell 
lines and verified that septin-2 knockdown was indeed lost 
in KD9 cells, while the KD11 cells had retained septin-2 
knockdown (Supplementary Figure 3). Therefore, we 
proceeded with analysis using KD11 cells. As expected, a 
principal component analysis of three biological replicates 
of WT, Plasmid C, and KD11 revealed separate clusters 
when comparing principal component 1 (PC1) and PC2 
scores (Figure 3). In contrast, for KD9 sample, the 3 
biological replicates were very scattered (data not shown). 
Therefore, any further analysis or validation of KD9 was 
not included.
Mass spectrometry of the control and knockdown 
cells identified 19976 unique peptides corresponding to 
3565 unique proteins. Of those, only one peptide/protein in 
Plasmid C exhibited an absolute fold change greater than 1 
with a q-value < 0.05 compared to WT (Figure 4A). This 
result allowed us to conclude that there was no significant 
difference between both control cell populations. Conversely, 
5% of all peptides in KD11 cells revealed relative fold 
change greater than 1 (q < 0.05) compared to WT cells. In 
Figure 2: Stable septin-2 knockdown shows a decrease in proliferation. (A) Gene expression levels of septin-2 in KD9 and 
KD11 compared to WT and Plasmid C control levels determined by quantitative PCR (qPCR). (B) Verification of septin-2 knockdown 
at protein level visualized by Western blot. A single blot was probed simultaneously for septin-2 and GAPDH as a loading control. The 
original blot can be seen in Supplementary Figure 4. (C) Relative band density of (B) normalized to GAPDH. (D) Proliferation rates of KD9 
and KD11 compared to control WT and Plasmid C were assessed at 72 and 96 hours by total live cell counts.
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addition, 93.5% of those peptides identified as exhibiting 
substantial expression differences displayed a lower peak 
area in KD11 compared to WT, indicating a majority of 
peptides were downregulated (Figure 4B). Representative 
examples of peak-area of four peptide sequences from the 
proteins galetin-3 binding protein (LFALS3BP), transketolase 
(TKT), poly(A) binding protein (PABPC4), and enolase-
1(ENO1) show differential expression between control 
and knockdown cells. KD11/WT peak area ratios were 
calculated for LFALS3BP (0.051, q = 0.012), TKT (0.081, 
q = 0.0012), PABPC4 (0.50, q = 0.011), and ENO1 (632.7, 
q = 0.30) (Figure 4C). It is interesting to note that, all four 
of these proteins have previously been shown to play a role 
in tumorigenesis [18–21]. Heat maps were constructed to 
illustrate the clustering of the 231 differentially expressed 
proteins in each of the three replicates of WT, Plasmid C, and 
KD11 (Figure 5A) and representative peptides in the most 
differentially expressed proteins (Figure 5B). Comparison of 
both heat maps reveals an overall similar pattern of peak-area 
quantitation, with many of the proteins and peptide sequences 
within KD11 exhibiting downregulation compared to WT 
and Plasmid C controls.
Figure 3: Principal component analysis of WT, Plasmid C, and KD11 samples. WT, Plasmid C and KD11 show clustering in 
visualization of principal component 1(PC1) versus principal component 2 (PC2) (A) wherein WT is more dispersed and shows overlap 
with Plasmid C in PC1 vs PC3 (B). 
Figure 4: Volcano plot of fold change versus q-value of peak area for distinct peptides. Of the 19976 distinct peptides (3565 
proteins) identified, (A) only one peptide/protein (0%, red in inset pie chart) in Plasmid C and (B) 5.0% peptides in KD11 showed large 
difference (absolute fold change more than 1, and q < 0.05) against WT. Nearly 93.5% peptides showed lower peak-area (down regulation) 
in KD11. (C) Examples of peak-area/expression levels in replicates for four peptides are shown: 1. Galectin-3-binding protein (LGALS3BP, 
UniProtID: K7EKQ5), 2. Transketolase (TKT, P29401), 3. Poly(A) binding protein 4 (PABPC4, Q4VC03), 4. Enolase 1 (ENO1, P06733). 
The peptide sequence, KD11/WT peak-area ratio, and respective q-values are listed for each protein.
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Figure 5: Hierarchical clustering and heat map of differentially expressed proteins and peptides. (A) Clustering of the 
231 differentially expressed proteins. (B) Peptides in most differentially expressed proteins, for example, in ribosome binding protein 
1(Q9P2E9 (RRBP1, Ribosome binding protein 1 UniProtID: Q9P2E9) with 60 peptides, showing an overall similar pattern of peak-area 
quantitation. Peptides/proteins show mostly down regulation in KD11 samples, which form a distinct cluster.
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Finally, gene ontology (GO) analysis with 
differentially expressed proteins showed enrichment of 
proteasomal/ubiquitin in the biological process category 
and RNA binding in the molecular function category 
(Figure 6). Enrichment was also noted for terms related to 
the ribonucleoprotein complex and cytosol in the cellular 
component category. KEGG pathway analysis revealed 
citric acid cycle (TCA cycle) and spliceosome enrichment 
among differentially expressed proteins (Figure 6).
Representative proteins related to these pathways 
were further validated by immunoblot analysis in 
triplicate. Enolase, LDHA, Transketolase, and FASN 
expression in WT and KD11 was examined via Western 
blot (Figure 7A). Band density normalized to GAPDH 
revealed a 1.2-fold increase in Enolase expression from 
WT to KD11, although this change was not significant 
due to one replicate showing no increase. LDHA, 
Transketolase, and FASN levels in KD11 were 0.70-fold 
(p = 5.5 × 10–4), 0.43-fold (p = 0.001), and 0.35-fold (p 
= 2.5 × 10–5) lower relative to WT control. (Figure 7B).
DISCUSSION
For the first time, we have characterized septin-2 
function in EOC and examined its proteomic effects on 
a global level. Several biological pathways were found 
Figure 6: Gene ontology (GO) analysis using DAVID (https://david.ncifcrf.gov/). Proteins with differential expression (n = 231, 
q < 0.05, in KD11 versus WT is compared with proteins (n = 3334) that showed no differential expression. The former showed enrichment 
for proteasomal/ubiquitin related GO terms (q << 0.05, Bonferroni) in the biological process (BP) category. In cellular component (CC) and 
molecular function (MF) categories, differentially expressed proteins showed enrichment for ribonucleoprotein and RNA related terms. No 
enrichment was seen in the molecular function category. Differentially expressed proteins showed enrichment for KEGG pathways relating 
to citrate cycle/energy and spliceosome. 
Figure 7: Verification of enriched proteins identified by proteomic analysis. (A) Triplicate Western blot analysis of protein 
expression validated in both WT and KD11. Blots were probed for GAPDH, then subsequently stripped and re-probed for each individual 
validated protein. Original blots from all three replicates can be seen in Supplementary Figure 4. (B) Relative Band Densities of proteins in 
(a), normalized to GAPDH. *p < 0.05 **p < 0.005, ***p < 0.0005.
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to be differentially regulated in septin-2 knockdown 
ovarian cancer cells, exemplified by representative 
proteins from Figure 4C. Galectin-3 is a member of the 
β-galactoside binding protein family that is involved in 
diverse functions inherent to cancer, such as metastasis, 
immune surveillance, inflammation, apoptosis, molecular 
trafficking, and mRNA splicing [22]. Transketolase is a 
pentose phosphate pathway enzyme essential for cancer 
growth due to its ability to control NADPH production and 
counteract oxidative stress [20]. Poly(A) binding protein 
is a highly conserved protein that plays an important 
role in mRNA stabilization and translation [23], which 
controls cell growth, proliferation, and differentiation [24]. 
Enolase1, found to be differentially expressed in cancer, is 
a key glycolytic enzyme that catalyzes 2-phosphogylgerate 
to phosphoenolpyruvate in the last steps of the glycolytic 
catabolic pathway [25].
Of these pathways identified, it was most expected 
that autophosphorylation and proteasomal/ubiquitin 
protein functions were affected by septin-2 knockdown. 
It has been previously established that proper control 
of septins’ phosphorylation status is required for the 
completion of cytokinesis [26]. In fungus, Meseroll et al 
(2013) discovered that changes in specific phosphorylation 
sites on septins (Cdc3p and Cdc11p) leads to the 
disruption of higher order septin structures, indicating 
septin phosphorylation is also a vital regulator of their own 
structure formation [27].
Similar to phosphorylation, ubiquitination 
represents another important septin post-translational 
modification. Septins have an established role interacting 
with proteins involved in degradation pathways, such as 
ubiquitin ligases and de-ubiquitylating enzymes, which 
modulates protein turnover [12, 28, 29]. Recently, it has 
also been reported that SUMOylation of human septins 
is a critical process contributing to proper septin filament 
bundling and cytokinesis [30]. Unlike ubiquitin, SUMO 
(small ubiquitin-like modifiers) modification does not 
always lead to protein degradation, as SUMOylation can 
also modulate localization, interaction, and activity of the 
target protein [31]. Ribet et.al (2017) reported that septin-7 
is constitutively SUMOylated throughout the cell cycle, 
and septin variants that are unable to be SUMOylated halt 
septin bundle formation and lead to defects in cytokinesis, 
highlighting its crucial role in septin filament bundling and 
cell division [30].
GO analysis revealed that septin-2 is also involved 
in post-transcriptional modifications, as the spliceosome 
pathway was found to be enriched among septin-2 
regulated proteins (Figure 6). This result suggests 
that septin-2 plays a major role in the editing of both 
precursor messenger RNA (pre-mRNA) and proteins. 
The spliceosome, a large molecular complex involved 
in the removal of non-coding introns from pre-mRNA, 
represents a potential oncogenic target as evidence has 
shown that tumors rely on normal spliceosome function for 
cell survival [32, 33]. In addition, Poly(A) binding protein, 
which we reported as an example of a differentially 
expressed protein (Figure 4C), is a translation initiation 
factor that binds to the mRNA 3’poly(A) tail [24] and 
influences cell growth and survival. Since we have 
shown that the knockdown of septin-2 promotes irregular 
expression of a multitude of pathways related to mRNA 
and protein modifications, it seems reasonable that its 
downregulation would also affect tumor cell growth.
As the depletion of septins can lead to cytokinesis 
failure, it is logical that cellular proliferation would 
subsequently be affected [30]. In this study, we observed a 
reduction in proliferation with septin-2 knockdown (Figure 
2D). Corroborating results from our study in EOC, Zhang 
et al (2016) treated breast cancer cells with the broad 
septin inhibitor forchlorfenuron (FCF) and also observed 
a decrease in cell proliferation [17], which they attributed 
to the suppression of MEK and ERK1/2 (extracellular 
signal-regulated kinase 1/2) signaling [17]. Another study 
showed that septin-8 interacts with MAPK5 (mitogen 
activated protein kinase 5), further suggesting that septins 
play a role in the MAPK/ERK pathway [34]. Septin-9 has 
also been implicated in cell proliferation, as a septin-9 
variant SEPT9_i1 binds to c-Jun-N terminal kinase (JNK), 
preventing its degradation and therefore promoting tumor 
cell proliferation [4]. In addition, another septin-9 variant 
SEPT9_i3 has been found to be phosphorylated by cell-
cycle-dependent kinase 1 (CDK1), controlling entry into 
mitosis and promoting cell survival and proliferation [35]. 
These investigations highlight that septin-2, and septins in 
general, play an important role in cellular proliferation and 
potentially promote tumor growth.
Interestingly, the most novel conclusion drawn 
from this investigation was the robust enrichment seen 
in cellular metabolism and energy dynamics in proteins 
affected by septin-2 downregulation. This novel finding 
regarding septin-2 is in agreement with previous 
studies reporting on septin functions related to energy 
metabolism. One study found that in Shigella bacteria, 
host cell glycolysis becomes dysfunctional when septin-2 
and septin-7 are depleted, indicating that septins may play 
a role in the modulation of glycolysis [36]. An additional 
study identified that fungal septins FaCdc3 and FaCdc12 
are required for lipid metabolism [37]. Moreover, 
septin-9 was found to induce lipid droplet growth through 
binding to phosphatidylinositol-5-phosphate (PtdIns5P), 
a phospholipid with a well-established role in dynamics 
and intracellular membrane trafficking [38]. PtdIns5P 
binding in turn controls septin-9 filament formation 
and its interaction with microtubules [39]. Furthermore, 
septin-11 was found to be expressed in human adipocytes 
and upregulated in obese individuals. SEPT11 mRNA was 
positively correlated with markers of insulin resistance in 
adipose tissue, and silencing of septin-11 muted insulin 
signaling and insulin-induced lipid accumulation in 
adipocytes [40].
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Our findings, however, represent the first time a septin 
family member has been implicated in cellular metabolism 
as it relates to tumorigenesis. Acetyl-CoA, one of the 
pathways most differentially expressed by septin-2, is a key 
metabolic player that links glycolysis, fatty acid oxidation, 
ketogenesis, amino acid metabolism, the TCA cycle, and 
lipid synthesis [41]. In normoxic conditions, acetyl-CoA is 
derived from glucose. However, under hypoxic conditions 
like in cancer, acetyl-CoA has been to found to derive from 
acetate, suggesting that targeting the acetyl-CoA pathway 
in cancer could represent a viable treatment option [42]. 
The TCA cycle, another important metabolic pathway, was 
also deregulated in the septin-2 knockdown clones. While 
previous dogma stated that tumor cells do not utilize the TCA 
cycle for energy, it has now been found that some cancer 
cells with deregulated oncogenes and tumor suppressor 
genes actually do rely on the TCA cycle [43]. In addition, 
the metabolic proteins transketolase and enolase, which are 
involved in glycolysis and the pentose phosphate pathway, 
respectively, were found to be differentially expressed by 
septin-2 inhibition (Figure 4C), demonstrating that septin-2 is 
involved in various facets of cellular metabolism within EOC. 
Pathways related to metabolism and energy production have 
previously been found to contribute to EOC tumorigenesis, 
as it has been shown that glycolysis drives chemoresistance 
in EOC and that high levels of fatty acid synthase (FASN) 
contribute to tumor cell growth through the promotion of 
human epidermal growth factor [44, 45]. Therefore, it can be 
hypothesized that the inhibition of septin-2 would exhibit a 
therapeutic effect in EOC via suppression of tumor metabolic 
pathways.
Overall, our study demonstrates the novel finding 
that septin-2 is involved in EOC pathogenesis. This 
investigation represents a springboard for future studies to 
determine the efficacy of septin-2 inhibition, in addition to 
more clearly elucidating its diverse mechanistic pathways 
in EOC tumorigenesis. While our proteomics study was 
performed in a serous ovarian cancer cell line, it would 
be interesting to repeat the stable knockdown experiment 
in a clear cell EOC line, since septin-2 was also found 
to be overexpressed in this histopathology. Additionally, 
both in vitro and in vivo studies could be performed to 
confirm that inhibition of septin-2 affects cell viability and 
tumor growth in order to determine if targeting of septin-2 
synergizes with platinum-based chemotherapeutics.
MATERIALS AND METHODS
Cell culture
SKOV3 wild type (SKOV3WT) cells were obtained 
from American Type Culture Collection (ATCC) and were 
cultured at low passage in Dulbecco’s Modified Eagle 
Medium supplemented with 10% fetal bovine serum and 
1% penicillin/streptomycin in a humidified incubator at 
37°C/5% CO2.
Septin-2 silencing with shRNA
shRNA for human septin-2 (Santa Cruz 
Biotechnology, sc-40936-SH) or scrambled oligonucleotide 
control shRNA (Plasmid-C; Santa Cruz Biotechnology, 
sc-108066) was transfected into SKOV3WT cells using 
Lipofectomine® 2000 (Invitrogen, 11668) following the 
manufacturer’s instructions. Individual single cells were 
selected by culturing under the pressure of 5 ug/mL of 
puromycin (Research products International, 58-58-2), and 
clonal populations were allowed to expand. Phenotypes of 
the clones were evaluated by Western blotting using anti 
Septin-2 antibody (Novus Biologicals, NBP1-85212).
Proliferation assay
SKOV3WT, Plasmid C, and knockdown lines 
(KD9 and KD11) were plated at equal densities in 
100 × 20 mm plates. Cells were trypsinized at 72 and 
96 hours, and replicates of three were counted using a 
hemocytometer with trypan blue staining to compare 
proliferation rates. The experiment was repeated three 
times and error bars represent standard deviation. 
Statistical significance was determined by an unpaired, 
two-tailed Student t-test, where p < 0.05 was considered 
significant. To ensure all cells had comparable viabilities, 
WT, Plasmid C, KD9, and KD11 were plated at equal 
densities in 60 × 20 mm plates. Cells were trypsinized at 
72 hours and replicates of three were assessed via trypan 
blue staining and live/dead counts using a Nexcelom 
Biosciences Auto T4 Cellometer.
Immunohistochemistry and confocal 
immunofluorescent microscopy
Formalin-fixed paraffin embedded human 
ovarian tissue slides were obtained from the Women 
and Infants Pathology Department. The human ovarian 
tissue microarray was obtained from US Tissue Biomax 
(OV802a). Slides obtained from Women and Infants were 
baked at 65°C for two hours, and the microarray for 20 
minutes. All slides were subsequently washed in xylene, 
100% ethanol, 95% ethanol, 70% ethanol, deoxygenated 
water, and FTA Hemagglutination Buffer. Antigen retrieval 
was then performed using DAKO antigen retrieval 
solution (10x) (Agilent, S1699), heated to 95°C for 20 
minutes. Slides were then blocked with 5% horse serum 
in FTA Hemagglutination Buffer and incubated overnight 
in primary Septin-2 antibody (Santa Cruz, sc-20408) at 
4°C. Secondary antibody, Alexa Fluora 488-conjugated 
donkey anti-Goat IgG (H+L) (Thermo Fisher Scientific, 
A-11055) was then added to slides following incubation 
in the dark for one hour at room temperature. Slides were 
washed in between steps with FTA Hemagglutination 
Buffer and were cover-slipped with DAPI containing 
mounting medium (Vector Laboratories, H-1200). While 
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this primary Septin-2 antibody has been discontinued, 
results were replicated in a separate staining experiment 
in which the overexpression of septin-2 in serous and 
clear cell histopathogies compared to benign controls 
was confirmed with a commercially available antibody 
(Thermo Fisher Scientific PA5-27517). This antibody 
was also used to perform confirmatory staining of WT 
and KD11 cells. Secondary antibody Dylight 488 anti-
rabbit IgG (Vector Laboratories, DI-1488) was then used 
(Supplementary Figure 1).
Images were acquired using a Nikon E800 
microscope (Nikon Inc. Mellville, NY, USA) and an RT3 
SPOT camera (Diagnostic Instruments, Sterling Heights, 
MI, USA). Random sampling of ten fields was based on 
DAPI staining. Mean intensity (used as a measurement 
for the tissue microarray as all areas for tissue were 
uniform) or integrated optical density (IOD) expressed as 
area*mean/1E+07, was acquired using a 40X objective. 
IOD was reported with staining performed with tissue 
obtained from our institution, as the size of each sample 
was variable. Statistical significance was determined by 
an unpaired, two-tailed Student t-test, where p < 0.05 was 
considered significant.
Western blot
Protein was extracted from cell pellets in Cell 
Lysis Buffer (Cell Signaling, 9803) with 1 mM of 
PMSF, according to the manufacturer’s protocol. The 
concentration of extracted proteins was determined by DC 
Protein Assay (Bio-Rad Laboratories, 5000116). Western 
blot analysis was performed by loading equal amounts 
of protein boiled at 70°C with Novex Sample Reducing 
Agent (Life Technologies, NP009) and NuPAGE LDS 
sample buffer (ThermoFisher Scientific, NP0007) into 
a 4–12% gradient NuPAGE Novex Bis-Tris gel (Life 
Technologies, NP0321BOX). The gel was then transferred 
using a semi-dry transfer to methanol-activated 0.2 μm 
PVDF membranes (Bio-Rad, 162-0177) at 0.12-0.24A 
for 80 minutes. Membranes were blocked in 5% milk in 
phosphate-buffered saline with 0.05% Tween 20 (PBS-T) 
for 30 minutes at room temperature. Finally, membranes 
were incubated in primary antibody diluted in 5% 
milk in PBS-T overnight at 4°C, and then in secondary 
antibody diluted in 5% milk in PBS-T for 1 hour at room 
temperature, with PBS-T washes in between. Amersham 
ECL Prime Western Blot Detection System (GE 
Healthcare, RPN2232) was employed for detection of the 
HRP-tagged secondary antibodies. The Biorad Chemidoc 
MP Imaging System was used to image all blots. GAPDH 
was used as a loading control. Antibodies and respective 
dilutions used are as follows:
GAPDH (Cell Signaling, 2118, [1:2000])
Septin-2 (Novus Biologicals, NBP1-85212, [1:500])
LDHA (Cell Signaling, 3582S, [1:1000])
FASN (Cell Signaling, 3180S, [1:1000])
Enolase (Santa Cruz Biotechnology, sc-100812 [1:500])
 Transketolase (Santa Cruz Biotechnology, sc-390179) 
[1:500]).
Quantitative PCR
RNA was extracted from cells by Trizol /LiCl 
precipitation. Total RNA (1000 ng) was then reverse 
transcribed into cDNA using the iScript cDNA Synthesis 
Kit (Bio-Rad, 1708890), following the manufacturer’s 
protocol. Quantitative PCR was performed in triplicate 
by loading 1 μl cDNA reaction, 1 μM forward and reverse 
validated Septin-2 primers (Origene HP232247), 10 μl 
SYBR Green (Applied Biosciences [ABI], 4367659) 
and 5 μl RNAse-free water to each well. Samples were 
run using the ABI 7500 Fast Real-Time PCR System. 
Data was then analyzed using the ΔΔCt method. All gene 
expression levels were normalized to 18s rRNA.
Densitometry
Densitometry analysis of Western blots was 
performed using image J. Blot images were analyzed 
in 8-bit JPEG format, using the “analyze gel” function. 
Relative band densities were normalized to GAPDH 
loading control.
Sample preparation for LC-MS/MS analysis
Cell pellets were suspended in lysis buffer (8 M urea, 
1 mM sodium orthovanadate, 20 mM HEPES, 2.5 mM 
sodium pyrophosphate, 1 mM β-glycerophosphate, pH 
8.0, 20 min, 4°C), sonicated and cleared by centrifugation 
(14 000 × g, 15 min, 4°C). Protein concentration was 
measured (Pierce BCA Protein Assay, Thermo Fisher 
Scientific, IL, USA) and a total of 100 µg of protein per 
sample was digested with trypsin. Tryptic peptides were 
desalted using C18 Sep-Pak plus cartridges (Waters, 
Milford, MA, USA) and were lyophilized for 48 hours to 
dryness. The dried eluted peptides were reconstituted in 
buffer A (0.1 M acetic acid) at a concentration of 1 µg/µl, 
and 5 µl was injected for each analysis.
The LC-MS/MS was performed on a fully 
automated proteomic technology platform [46, 47] that 
includes an Agilent 1200 Series Quaternary HPLC system 
(Agilent Technologies, Santa Clara, CA, USA) connected 
to a Q Exactive Plus mass spectrometer (Thermo Fisher 
Scientific, Waltham, MA, USA). The LC-MS/MS set 
up was used as described previously [48]. Briefly, the 
peptides were separated through a linear reversed-phase 
90 minutes gradient from 0% to 40% buffer B (0.1 M 
acetic acid in acetonitrile) at a flow rate of 3 µl /min 
through a 3 µm 20 cm C18 column. The electrospray 
voltage of 2.0 kV was applied in a split flow configuration, 
and spectra were collected using a top-9 data-dependent 
method. Survey full scan MS spectra (m/z 400-1800) 
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were acquired at a resolution of 70,000 with an AGC 
target value of 3 × 106 ions or a maximum ion injection 
time of 200 ms. The peptide fragmentation was performed 
via higher-energy collision dissociation with the energy 
set at 28 NCE. The MS/MS spectra were acquired at a 
resolution of 17,500, with a targeted value of 2 × 104 
ions or a maximum integration time of 200 ms. The ion 
selection abundance threshold was set at 8.0 × 102 with 
charge state exclusion of unassigned and z = 1, or 6–8 ions 
and dynamic exclusion time of 30 seconds.
Database search
Peptide spectrum matching of MS/MS spectra of 
each file was searched against a species-specific database 
(UniProt; downloaded 2/1/2015) using MASCOT v. 2.4 
(Matrix Science, Ltd, London, UK). A concatenated 
database containing “target” and “decoy” sequences was 
employed to estimate the false discovery rate (FDR) 
[49]. Msconvert from ProteoWizard (v. 3.0.5047), using 
default parameters and with the MS2Deisotope filter 
on, was employed to create peak lists for Mascot. The 
Mascot database search was performed with the following 
parameters: trypsin enzyme cleavage specificity, 2 possible 
missed cleavages, 10 ppm mass tolerance for precursor 
ions, 20 mmu mass tolerance for fragment ions. Search 
parameters permitted variable modification of methionine 
oxidation (+15.9949 Da) and static modification of 
carbamidomethylation (+57.0215 Da) on cysteine. The 
resulting peptide spectrum matches (PSMs) were reduced 
to sets of unique PSMs by eliminating lower scoring 
duplicates. To provide high confidence, the Mascot results 
were filtered for Mowse Score (>20). Peptide assignments 
from the database search were filtered down to a 1% 
FDR by a logistic spectral score as previously described 
[49, 50]. The mass spectrometry proteomics data have 
been deposited to the ProteomeXchange Consortium via 
the PRIDE partner repository with the dataset identifier 
PXD010166. Raw data is also available within the 
Supplementary Dataset file of this manuscript.
Relative quantitation of the identified peptides
Relative quantification of peptide abundance was 
performed via calculation of selected ion chromatograms 
(SIC) peak areas. Retention time alignment of individual 
replicate analyses was performed as previously described 
[51]. Peak areas were calculated by inspection of SICs 
using in-house software programmed in R 3.0 based on 
the Scripps Center for Metabolomics’ XCMS package 
(version 1.40.0). This approach performed multiple passes 
through XCMS’ central wavelet transformation algorithm 
(implemented in the centWave function) over increasingly 
narrower ranges of peak widths, and used the following 
parameters: mass window of 10 ppm, minimum peak 
widths ranging from 2 to 20 seconds, maximum peak width 
of 80 seconds, signal to noise threshold of 10 and detection 
of peak limits via descent on the non-transformed data 
enabled. SIC peak areas were determined for every peptide 
that was identified by MS/MS. In the case of a missing MS/
MS for a particular peptide, in a particular replicate, the SIC 
peak area was calculated according to the peptide’s isolated 
mass and the retention time calculated from retention time 
alignment. A minimum SIC peak area equivalent to the 
typical spectral noise level of 1000 was required of all data 
reported for label-free quantitation. Individual SIC peak 
areas were normalized to the peak area of the standard 
synthetic peptide DRVYHPF that was exogenously spiked 
prior to reversed-phase elution into the mass spectrometer. 
Quantitative analysis was applied to replicate experiments.
Bioinformatics analyses
To select peptides that showed a statistically 
significant change in abundance between control vs 
treatment cells, q-values for multiple hypothesis tests 
were calculated based on p-values from two-tailed 
unpaired Student’s t tests using the R package QVALUE 
as previously described [52, 53]. Peptide peak-areas are 
summed to get protein-level quantification where required 
[54]. All calculations were done in R programming 
language and volcano plot/graphs were plotted in Excel.
Principal component analysis (PCA) and 
hierarchical clustering/heat map were also performed in 
R. Gene ontology (GO) analysis was performed using 
Enrichr (http://amp.pharm.mssm.edu/Enrichr/) for 
differentially expressed peptides/proteins [54] in KD11 
versus WT against the background of unchanged proteins.
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